Injection Use and Practices in Uganda - EDM Research Series No. 014: OTHER DOCUMENTS IN THE DAP RESEARCH SERIES

Injection Use and Practices in Uganda - EDM Research Series No. 014
(1994; 54 pages)

Índice de contenido

ACKNOWLEDGEMENTS
1. INTRODUCTION
	1.1 Problem statement
	1.2 Objectives of the study
	1.3 Background to the country situation
		1.3.1 Health care in Uganda and injection use
		1.3.2 Sources of equipment and injectables
2. METHODOLOGY
	2.1 Sampling frame
	2.2 User-oriented methods
		2.2.1 Interviews with key informants
		2.2.2 Structured household interviews
		2.2.3 Methodological problems encountered with the household survey
	2.3 Provider-oriented methods
3. EXTENT OF INJECTION USE
	3.1 Prevalence of injection use
	3.2 Prevalence of specific types of injections
	3.3 Sources of injections
		3.3.1 Home possession of injection equipment and injectables
		3.3.2 Qualifications of provider who administered last injection
	3.4 Prevalence of injections at various medical facilities
	3.5 Evaluation of the appropriateness of injection use
4. HYGIENE OF INJECTION PRACTICE
	4.1 Hygiene of injections in Ankole
	4.2 Hygiene of injections in Busoga
		4.2.1 Injecting equipment
		4.2.2 Before injecting
		4.2.3 During injecting
		4.2.4 After injecting
		4.2.5 Summary
	4.3 Injection complications
5. POPULARITY OF INJECTIONS
6. CONCLUSIONS AND RECOMMENDATIONS
	6.1 Overview of results including main findings
	6.2 Recommendations
		6.2.1 Interventions
REFERENCES
LIST OF APPENDICES
	Appendix 1
	Appendix 2
	Appendix 3
OTHER DOCUMENTS IN THE DAP RESEARCH SERIES

OTHER DOCUMENTS IN THE DAP RESEARCH SERIES

N°. 1	Injection practices research
N°. 2	How to investigate drug use in communities (available also in French)
N°. 3	Operational research on the rational use of drugs
N°. 4	Development of indicators for monitoring national drug policies
N°. 5	People’s perception and use of drugs in Zimbabwe
N°. 6	Operational research in the Action programme on Essential Drugs: Report of an informal consultation
N°. 7	How to investigate drug use in health facilities: Selected drug use indicators (available also in French and Spanish)
N°. 8	Stability of injectable oxytocics in tropical climates: Results of field surveys and simulation studies on ergometrine, methylergometrine and oxytocin
N°. 9	Prescription des antibiotiques dans trois pays d’Afrique de l’Ouest Mauritanie, Niger et Sénégal
N°. 10	Self-medication and its impact on essential drugs schemes in Nepal
N°. 11	Injection practices: A case study in Thailand
N°. 12	Stability of oral oxytocics in tropical climates
N°. 13	Stability of essential drugs in tropical climates: Zimbabwe

DAP Research Series No. 14

In 1981 WHO’s Action Programme on Essential Drugs was established to provide operational support to countries in the development of national drug policies based on essential drugs and to work towards the rational use of drugs.

The Programme seeks to ensure that all people, wherever they may be, are able to obtain the drugs they need at a price that they and their country can afford; that these drugs are safe, effective and of good quality; and that they are prescribed and used rationally.

Research analysing the impediments to developing and managing sound national drug policies and programmes is an important element of country support activities. The Programme undertakes and promotes operational research aimed at filling some of the many gaps in existing knowledge about the best means of selecting, procuring and distributing drugs, and their use by prescribes and consumers.

This document is part of a series reporting on Action Programme research activities and guidelines.

Research that leads to breakthroughs in pharmaceutical technology or in highly sophisticated and expensive techniques of biomedical practice may superficially appear to be more “glamorous”. But the operational research that WHO’s Action Programme on Essential Drugs undertakes has a direct bearing on the ways in which vital medicines can be made available and accessible to the greatest number of people.

Action Programme on Essential Drugs, World Health Organization, 1211 Geneva 27, Switzerland